| Bristol-Myers Squibb Company (BMY) | |||
|---|---|---|---|
| 59.67 0.53 (0.9%) | 01-24 16:00 | ||
| Open: | 59.11 | Pre. Close: | 59.14 |
| High: | 59.995 | Low: | 59.1 |
| Volume: | 12,325,719 | Market Cap: | 121,022(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 70.07  One year: 81.85 |
| Support: | Support1: 56.79 Support2: 54.81 |
| Resistance: | Resistance1: 59.99 Resistance2: 70.07 |
| Pivot: | 56.83 |
| Moving Averages: | MA(5): 57.85 MA(20): 56.92 MA(100): 54.72 MA(250): 49.97 |
| MACD: | MACD(12,26): 0.27 Signal(12,26,9): -0.07 |
| %K %D: | %K(14,3): 90.23 %D(3): 77.05 |
| RSI: | RSI(14): 66.81 |
| 52-Week: | High: 61.08 Low: 39.35 Change(%): 20.3 |
| Average Vol(K): | 3-Month: 10954 10-Days: 9091 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 59.996 - 60.205 | 60.205 - 60.396 |
| Low: | 58.491 - 58.764 | 58.764 - 59.013 |
| Close: | 59.24 - 59.618 | 59.618 - 59.964 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BMY ] has closed Bollinger Bands are 7.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - General | |
| Shares Out. (M) | 2030.00 |
| Shares Float (M) | 2020.00 |
| % Held by Insiders | 0.12 |
| % Held by Institutions | 78.54 |
| Shares Short (K) | 27660 |
| Shares Short Prior Month (K) | 25770 |
| Stock Financials | |
|---|---|
| EPS | -3.580 |
| Book Value (p.s.) | 8.450 |
| Profit Margin | -15.30 |
| Operating Margin | 18.48 |
| Return on Assets (ttm) | 6.1 |
| Return on Equity (ttm) | -31.3 |
| Qtrly Rev. Growth | 8.4 |
| Gross Profit (p.s.) | 17.729 |
| Sales Per Share | 23.369 |
| EBITDA (p.s.) | 9.438 |
| Qtrly Earnings Growth | -35.80 |
| Operating Cash Flow (M) | 15000.00 |
| Levered Free Cash Flow (M) | 17520.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | -16.67 |
| PEG Ratio | |
| Price to Book value | 7.06 |
| Price to Sales | 2.55 |
| Price to Cash Flow | 8.08 |
| Stock Dividends | |
|---|---|
| Dividend | 0.620 |
| Dividend Yield | 0.01 |
| Dividend Growth | |
